Clinical Trial Update: A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis [Phase 4]

View source ↗

Summary

This document reports results from a Phase 4 trial evaluating quality of life and safety of 1% pimecrolimus cream in pediatric atopic dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Pimecrolimus Cream 1% (pimecrolimus)

Snippet

Sponsor: Novartis | Conditions: Atopic Eczema | Phase 4 | Status: COMPLETED